Protective effects of uric acid on nigrostriatal system injury induced by 6-hydroxydopamine in rats

National Medical Journal of China

Volumn 90, Issue 19, 2010, Pages 1362-1365

  Wang, Li Jun ^a   Luo, Wei Feng ^a   Wang, Heng Hui ^a   Ni, Gui Hua ^a   Ye, Yan ^a   Li, Dan ^a   Liu, Chun Feng ^a  

^a THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

6 hydroxydopamine; Behavior; Dopamine; Parkinson disease; Rats; Uric acid

Indexed keywords

DOPAMINE; HOMOVANILLIC ACID; OXIDOPAMINE; SODIUM CHLORIDE; URIC ACID; DOPAMINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; FOREFOOT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LOCOMOTION; MALE; MASS SPECTROMETRY; NERVE INJURY; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NIGRONEOSTRIATAL SYSTEM INJURY; NONHUMAN; PARKINSON DISEASE; RAT; ANIMAL; DRUG EFFECT; DRUG INTERACTION; NERVE CELL; SPRAGUE DAWLEY RAT;

ANIMALS; CORPUS STRIATUM; DRUG INTERACTIONS; HYDROXYDOPAMINES; MALE; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; URIC ACID;

EID: 84871464404     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2010.19.017     Document Type: Article

References (17)

1. Lockwood A H. Pesticides and parkinsonism: is there an etiological link? Curr Opin Neurol, 2000, 13:687-690.
2. Ballard P A, Tetrud J W, Langston J W. Permanent human parkinsonism due to l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP): seven cases. Neurology, 1985, 35: 949-956.
3. Janáky R, Ogita K, Pasqualotto B A, et al. Glutathione and signal transduction in the mammalian CNS. J Neurochem, 1999, 73: 889-902.
4. de Lau L M, Koudstaal P J, Hofman A, et al. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol, 2005, 58: 797-800.
5. Weisskopf M G, O'Reilly E, Chen H, et al. Plasma urate and risk of Parkinson's disease. Am J Epidemiol, 2007, 166: 561-567.
6. Church W H, Ward V L. Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation. Brain Res Bull, 1994, 33: 419-425.
7. Annanmaki T, Muuronen A, Murros K. Low plasma uric acid level in Parkinson's disease. Mov Disord, 2007, 22:1133-1137.
8. 2008, 41: 157-158.
9. Chang J W, Wachtel S R, Yong D, et al. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson disease: studies on medial forebrain bundle and striatal lesions. Neurosci, 1999, 88:617-628.
10. Mount D B, Kwon C Y, Zandi-Nejad K. Renal urate transport. Rheum Dis Clin North Am, 2006, 32:313-331.
11. Johnson R J, Kang D H, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension, 2003, 41:1183-1190.
12. Hooper D C, Scott G S, Zborek A, et al. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. Faseb J, 2000, 14:691-698.
13. Jenner P. Oxidative stress in Parkinsons disease. Ann Neurol, 2003, 53 Suppl 3: S26-36.
14. Luo W F, Schwarzschild M A, Xu K. Urate attenuates MPTP-induced dopmainergic toxicity in mice. The Society for neuroscience 37th annual meeting, 2007. San Diego, California, USA.
15. Ames B N, Cathcart R, Schwiers E, et al. Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA, 1981, 78:6858-6862.
16. Inoue S, Kawanishi S. Oxidative DNA damage induced by simultaneous generation of nitric oxide and superoxide. FEBS Lett, 1995, 371:86-88.
17. Kannellis J, Kang D H. Uric acid as a mediator of endothelial dysfunction, inflammation and vascular disease. Semin Nephrol, 2005, 25:39.